Expert Interview
Exploring the Factor XI landscape with a focus on NOVO/Anthos' abelacimab and Regeneron's REGN9933/7508
Ticker(s): NVO, REGN, Anthos TherapeuticsInstitution: University of Utah
- Associate Professor in the Division of Hematology and Hematologic Malignancies at the University of Utah.
- Research focused on complications affecting people with congenital bleeding disorders, specifically persons with hemophilia with inhibitors and pregnant women with bleeding disorders; clinical interest lies in the field of hemostasis and thrombosis.
How many patients do you manage for blood clotting?
Added By: nikki_adminOn a scale from 1-10 (10 being extremely excited), how excited are you about Anthos Therapeutics' abelacimab?
Added By: nikki_adminWhat are your thoughts on the current anticoagulation treatment landscape, including the advantages and disadvantages of existing therapies like warfarin, dabigatran, apixaban, and rivaroxaban? How do these treatments compare for different conditions such as atrial fibrillation and venous thromboembolism?
Added By: slingshot_insightsConsidering the emerging Factor XI inhibitors like Regeneron’s REGN7508/9933 and Anthos’ abelacimab, what are your views on their mechanisms of action, efficacy, and potential impact on bleeding risk? How do these approaches compare in terms of targeting Factor XI/XIa, and do you see one strategy being superior?
Added By: slingshot_insightsBased on early trial data, what are your impressions of the efficacy and safety profiles of these new Factor XI inhibitors? How do you assess trial designs comparing these therapies to standard anticoagulants like enoxaparin and apixaban, and what are the key factors in determining which product has the best potential for clinical adoption?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
